N-(4-羟基苯基)-3-甲基丁烷酰胺 | 723755-75-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-羟基苯基)-3-甲基丁烷酰胺
• 英文名称: 4-Isovalerylamino-phenol
• 英文别名: N-(4-hydroxy-phenyl)-3-methyl-butyramide；isovaleraminophen；N-(4-hydroxyphenyl)-3-methylbutanamide
• CAS: 723755-75-7
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: NFPBLAFQZXIWSX-UHFFFAOYSA-N

物化性质

• 沸点：
  394.6±25.0 °C(Predicted)
• 密度：
  1.131±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  4-(2-氯乙基)吗啉 、 N-(4-羟基苯基)-3-甲基丁烷酰胺 在 sodium isopropylate 作用下， 生成 1-(2-Morpholino-aethoxy)-4-isovalerylamino-benzol
  参考文献：
  名称：

  Pedrazzoli; Cipelletti, Bollettino Chimico Farmaceutico, 1966, vol. 105, # 5, p. 393 - 399

  摘要：

  DOI：
• 作为产物：
  描述：

  4-[(tert-butyldimethylsilyl)oxy]aniline 在 四丁基氟化铵 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 N-(4-羟基苯基)-3-甲基丁烷酰胺
  参考文献：
  名称：

  作为 20S 蛋白酶体刺激剂的 AM-404 衍生物的链长、取代模式和不饱和度分析。

  摘要：

  蛋白酶体介导的蛋白质降解是一个重要的细胞过程，由泛素依赖性蛋白酶体系统（UPS）和泛素非依赖性蛋白酶体系统（UIPS）执行。虽然这两个系统对于维持健康的细胞功能都是必需的，但许多疾病状态的特点是 UPS 活性降低，而 UIPS 本身无法维持适当的蛋白质水平。有人建议，20S 核心颗粒 (20S CP) 是 UIPS 中蛋白酶体的亚型，可以降解没有泛素标签的蛋白质，可以用小分子刺激，以帮助 20S CP 更快地接受和水解底物。此后发现了几种 20S CP 的小分子刺激剂，包括 AM-404（一种花生四烯酸衍生物）。AM-404 先前已被证明可以抑制脂肪酸酰胺水解酶活性。我们希望评估 AM-404 需要哪些结构成分来刺激 20S CP，长期目标是利用这些信息来设计具有更好的类药物品质的刺激器。我们合成了许多 AM-404 的衍生物，改变了链长、取代基和不饱和度。通过这一努力，我们获得了几种能够不同程度刺激

  DOI：

  10.1016/j.bmcl.2018.12.030

文献信息

• High-fluidity polycarbonates and process for preparing them
  申请人：ENICHEM S.p.A.

  公开号：EP0409312A2

  公开（公告）日：1991-01-23

  Linear, thermoplastic, aromatic polycarbonates having an average viscosimetric molecular weight comprised within the range of from 10,000 to 30,000, endowed with high fluidity in the molten state, are obtained by means of the use of chain capping agents of phenol-amidic nature, having the general formula: wherein: R, R₁, which can be either equal to, or different from, each other, are H or CH₃; R₂ is an either linear or branched alkyl radical, containing from 1 to 7 carbon atoms, or a cycloalkyl or alkylene-cycloalkyl radical of from 5 to 7 carbon atoms, with said alkyl, cycloalkyl or alkylene-cycloalkyl radicals possibly bearing a halogen atom.

  线性、热塑性、芳香族聚碳酸酯的平均粘度分子量在 10,000 至 30,000 之间，在熔融状态下具有高流动性，可通过使用具有通式的苯酚-氨基性质的链封端剂获得： 其中 R、R₁ 可以是 H 或 CH₃，也可以互不相同； R₂ 是含有 1 至 7 个碳原子的直链或支链烷基，或含有 5 至 7 个碳原子的环烷基或亚烷基环烷基，所述烷基、环烷基或亚烷基环烷基可能含有卤素原子。
• Treatment of spasticity, convulsions by isovaleric acid derivatives CNS depressants
  申请人：NPS PHARMACEUTICALS, INC.

  公开号：EP1516619A2

  公开（公告）日：2005-03-23

  Preparations and extracts of valerian, as well as isovaleramide, isovaleric acid, and its pharmaceutically acceptable salts, esters, and substituted amides, exhibit clinically significant pharmacological properties which implicate a treatment for a variety of pathological conditions, including spasticity and convulsions, which are ameliorated by effecting a mild depression of CNS activity. The compositions in question generally are non-cytotoxic and do not elicit weakness or seductive activity at doses that are effective for the symptomatic treatment of such pathological conditions.

  缬草的制剂和提取物以及异戊酰胺、异戊酸及其药学上可接受的盐、酯和取代酰胺具有显著的临床药理特性，可用于治疗各种病症，包括痉挛和抽搐，这些病症可通过轻度抑制中枢神经系统的活性而得到改善。这些成分一般不具有细胞毒性，在对症治疗此类病症有效的剂量下，不会引起虚弱或诱导性活动。
• Fenretinide Derivatives Act as Disrupters of Interactions of Serum Retinol Binding Protein (sRBP) with Transthyretin and the sRBP Receptor
  作者：José Angel Campos-Sandoval、Clara Redondo、Gemma K. Kinsella、Akos Pal、Geraint Jones、Gwen S. Eyre、Simon C. Hirst、John B. C. Findlay

  DOI：10.1021/jm200256g

  日期：2011.7.14

  Serum retinol binding protein (sRBP) is released from the liver as a complex with transthyretin (TTR), a process under the control of dietary retinol. Elevated levels of sRBP may be involved in inhibiting cellular responses to insulin and in generating first insulin resistance and then type 2 diabetes, offering a new target for therapeutic attack for these conditions. A series of retinoid analogues were synthesized and examined for their binding to sRBP and their ability to disrupt the sRBP-TTR and sRBP-sRBP receptor interactions. A number inhibit the sRBP-TTR and sRBP-sRBP receptor interactions as well as or better than Fenretinide (FEN), presenting a potential novel dual mechanism of action and perhaps offering a new therapeutic intervention against type 2 diabetes and its development. Shortening the chain length of the FEN derivative substantially abolished binding to sRBP, indicating that the strength of the interaction the polyene chain region. Differences in potency against the sRBP-TTR and sRBP-sRBP receptor interactions suggest variant effects of the compounds on the two loops of sRBP guarding the entrance of the binding pocket that are responsible for these two protein-protein interactions.
• CYANO THIENOTRIAZOLODIAZEPINES AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20200199150A1

  公开（公告）日：2020-06-25

  The present invention provides compounds and pharmaceutically compositions thereof. The compounds and compositions are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.
• SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20200407371A1

  公开（公告）日：2020-12-31

  Provided herein are bifunctional compounds that bind a target protein (e.g., a selected protein) and/or induce ubiquitination for degradation of the target protein. In particular, provided are compounds that bind a bromodomain or bromodomain-containing protein (e.g., BET proteins) or histone methyltransferases (HMTs, e.g., enhancer of zeste homolog 1 (EZH1), or FKBP12) and can promote its degradation by recruiting it to the ubiquitin receptor RPN13 (e.g., RA190), for proteasomal degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating and/or preventing diseases (e.g., proliferative diseases, cancers, benign neoplasms, pathological angiogenesis, inflammatory diseases, and autoimmune diseases) and musculoskeletal diseases, and methods of inducing the degradation of a target (e.g., a target protein) by recruiting it to the ubiquitin receptor RPN13 of the proteasome in a subject by administering a compound or composition described herein.